ReviewImmunotherapy2016
Novel vaccines for glioblastoma: clinical update and perspective.
Review in Immunotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells.Nature genetics · 2024Article
- Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.Frontiers in immunology · 2024Review
- Current Status and Challenges of Vaccination Therapy for Glioblastoma.Molecular cancer therapeutics · 2023Article
- An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.Cancer communications (London, England) · 2022Review
- The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.Medical oncology (Northwood, London, England) · 2022Review
- Considerations when treating high-grade pediatric glioma patients with immunotherapy.Expert review of neurotherapeutics · 2021Article
- Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?Frontiers in immunology · 2021Review
- Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma.Frontiers in oncology · 2021Review
- Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review.International journal of general medicine · 2021Review
- Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation.Bioengineering (Basel, Switzerland) · 2019Article
- Harnessing the immune system in glioblastoma.British journal of cancer · 2018Review
- Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme.EBioMedicine · 2018Article
- Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.International journal of molecular sciences · 2018Review
- Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research.Cureus · 2018Review
- Glioblastoma under Siege: An Overview of Current Therapeutic Strategies.Brain sciences · 2018Review
- A Winning New Combination? Toward Clinical Application in Oncology.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma is the most common primary brain cancer. Aggressive treatment with surgery, radiation therapy and chemotherapy provides limited overall survival benefit. Glioblastomas have a formidable tumor microenvironment that is hostile to immunological effector cells and these cancers produce profound systemic immunosuppression. However, surgical resection of these tumors creates conditions that favor the use of immunotherapeutic strategies. Therefore, extensive surgical resection, when feasible, will remain part of the equation to provide an environment in which active specific immunotherapy has the greatest chance of working. Toward that end, a number of vaccination protocols are under investigation. Vaccines studied to date have produced cellular and humoral antitumor responses, but unequivocal clinical efficacy has yet to be demonstrated. In addition, focus is shifting toward the prospect of therapies involving vaccines in combination with immune checkpoint inhibitors and other immunomodulatory agents so that effector cells remain active against their targets systemically and within the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.